143 results on '"McMahon, Meagan"'
Search Results
2. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
3. Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site
4. Broadly neutralizing antibodies target a haemagglutinin anchor epitope
5. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial
6. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City
7. A serological assay to detect SARS-CoV-2 seroconversion in humans
8. Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses
9. Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner
10. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
11. Murine Broadly Reactive Antineuraminidase Monoclonal Antibodies Protect Mice from Recent Influenza B Virus Isolates and Partially Inhibit Virus Transmission in the Guinea Pig Model
12. Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner
13. Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies
14. A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice
15. Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice
16. Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models
17. Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model
18. Broadly neutralizing antibodies target a haemagglutinin anchor epitope
19. A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model
20. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice
21. Extracellular Matrix Enzymes and Immune Cell Biology
22. The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination
23. Novel epitopes of human monoclonal antibodies targeting the influenza virus N1 neuraminidase
24. Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase
25. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model
26. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial
27. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
28. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity
29. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City
30. Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice
31. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective
32. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
33. Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City
34. An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening
35. Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
36. SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
37. A serological assay to detect SARS-CoV-2 seroconversion in humans
38. Protection Against Influenza B Viruses by Human Monoclonal Antibodies that Target the Neuraminidase Active Site
39. Correction: ADAMTS5 is a critical regulator of virus-specific t cell immunity
40. Maturation of germinal center B cells after influenza virus vaccination in humans
41. Correction: ADAMTS5 Is a Critical Regulator of Virus-Specific T Cell Immunity
42. Broadly protective human antibodies that target the active site of influenza virus neuraminidase
43. Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice
44. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge
45. Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs
46. A HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model
47. Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome
48. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
49. ADAMTS7 extracellular matrix enzyme expression is required for optimal influenza-specific CD8+T cell immunity.
50. ADAMTS5 and its substrate versican play a critical role in influenza virus immunity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.